1. 290 COMPARATIVE EFFICACY OF CORTICOSTEROIDS FORMULATIONS FOR THE MANAGEMENT OF EOSINOPHILIC OESOPHAGITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. (14th September 2020) Authors: Ma, C; Feagan, B; Claveau, D; Landry, L; Baribeau, V; Beauchemin, C Journal: Diseases of the esophagus Issue: Volume 33(2020)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS. (7th March 2023) Authors: Sands, B E; Feagan, B; Gibble, T H; Traxler, K A; Morris, N; Li, X; Schreiber, S; Jairath, V; Armuzzi, A; Jones, J Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION. (21st February 2022) Authors: Crowley, E; Turner, D; Ma, C; Nguyen, T; McKay, H; Schneider, R; Silverberg, A; Muise, A; Feagan, B; Griffiths, A; Jairath, V Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient's with crohn's disease. (17th June 2017) Authors: Li, K; Chan, D; Pollack, P; Jacobstein, D; Brodmerkel, C; Gasink, C; Feagan, B; Sandborn, W; Rutgeerts, P; Hertogh, G De Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis. (27th May 2021) Authors: Sandborn, W; Ding, Z; Osterhout, R; Feagan, B; Danese, S; Jucov, A; Bhandari, B R; Raghupathi, K; Olson, A; Van Biene, C; Ford, J; Aranda, R; Levesque, B G; Bruey, J M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2. (15th January 2020) Authors: Chen, C; Rosario, M; Polhamus, D; Dirks, N; Zhang, W; Sun, W; Kisfalvi, K; Feagan, B; Sandborn, W; Vermeire, S; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S056 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. (25th January 2019) Authors: Sandborn, W J; Ferrante, M; Bhandari, B R; Berliba, E; Hibi, T; D'Haens, G Geert R; Tuttle, J; Krueger, K; Friedrich, S; Durante, M; Arora, V; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP55 Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis. (21st January 2022) Authors: Leong, R; Sands, B; Peyrin-Biroulet, L; Marano, C; Miao, Y; Izanec, J; Feagan, B; Rubin, D Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study. (27th May 2021) Authors: Loftus, E; Vermeire, S; Feagan, B; Yun, C; Hsieh, J; Liu, X; Zhao, S; Moerch, U; Sandborn, W J; Hibi, T Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. (21st January 2022) Authors: Atreya, R; Feagan, B; Shchukina, O; Jairath, V; Rieder, F; Hisamatsu, T; Siegmund, B; Rizzo, J; Kligys, K; Neimark, E; Song, A; Zambrano, J; Mallick, M; Cheng, E; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗